Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Gold

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Journal of Addiction Medicine|September 23, 2022
Differences in Self-identification of Opioid Overdose Risk and Naloxone Perceptions Between Therapeutic and Nontherapeutic Opioid PopulationsMatthew S Ellis, Zachary A Kasper, Mark Gold, et al.
Depression and Anxiety|June 23, 2016
A REVIEW OF KETAMINE ABUSE AND DIVERSIONSean Sassano-Higgins, Dave Baron, Grace Juarez, et al.
Pharmaceuticals (Basel, Switzerland)|December 28, 2021
Opioid Dosage Levels, Concurrent Risk Factors and Self-Perceptions among Chronic Pain, Opioid-Managed Individuals at Elevated Risk for Opioid OverdoseMatthew S Ellis, Zachary A Kasper, Mark Gold, et al.
Journal of the Neurological Sciences|February 20, 2020
Infectious diseases occurring in the context of substance use disorders: A concise reviewBhanu Prakash Kolla, Tyler Oesterle, Mark Gold, et al.
The Journal of the American Osteopathic Association|January 31, 2018
Conceptualizing Addiction From an Osteopathic Perspective: Dopamine HomeostasisDave Baron, Kenneth Blum, Anthony Chen, et al.
Journal of Addiction Medicine|May 19, 2015
Opioid use in pregnant women and the increase in neonatal abstinence syndrome: what is the cost?Kay Roussos-Ross, Gary Reisfield, Iain Elliot, et al.
Substance Use & Misuse|July 28, 2016
Should the United States Government Repeal Restrictions on Buprenorphine/Naloxone Treatment?Kenneth Blum, Mark Gold, H Westley Clark, et al.
Molecular Neurobiology|March 10, 2015
Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner?Kenneth Blum, Marcelo Febo, Panayotis K Thanos, et al.
Journal of the Neurological Sciences|July 16, 2022
Psychedelic drugs for psychiatric disordersSabrina Correa da Costa, Tyler Oesterle, Teresa A Rummans, et al.
Brain Sciences|December 23, 2023
Exercise Modifies the Brain Metabolic Response to Chronic Cocaine Exposure Inhibiting the Stria TerminalisColin Hanna, Rutao Yao, Munawwar Sajjad, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Journal of Addiction Medicine|September 23, 2022
Differences in Self-identification of Opioid Overdose Risk and Naloxone Perceptions Between Therapeutic and Nontherapeutic Opioid PopulationsMatthew S Ellis, Zachary A Kasper, Mark Gold, et al.
Depression and Anxiety|June 23, 2016
A REVIEW OF KETAMINE ABUSE AND DIVERSIONSean Sassano-Higgins, Dave Baron, Grace Juarez, et al.
Pharmaceuticals (Basel, Switzerland)|December 28, 2021
Opioid Dosage Levels, Concurrent Risk Factors and Self-Perceptions among Chronic Pain, Opioid-Managed Individuals at Elevated Risk for Opioid OverdoseMatthew S Ellis, Zachary A Kasper, Mark Gold, et al.
Journal of the Neurological Sciences|February 20, 2020
Infectious diseases occurring in the context of substance use disorders: A concise reviewBhanu Prakash Kolla, Tyler Oesterle, Mark Gold, et al.
The Journal of the American Osteopathic Association|January 31, 2018
Conceptualizing Addiction From an Osteopathic Perspective: Dopamine HomeostasisDave Baron, Kenneth Blum, Anthony Chen, et al.
Journal of Addiction Medicine|May 19, 2015
Opioid use in pregnant women and the increase in neonatal abstinence syndrome: what is the cost?Kay Roussos-Ross, Gary Reisfield, Iain Elliot, et al.
Substance Use & Misuse|July 28, 2016
Should the United States Government Repeal Restrictions on Buprenorphine/Naloxone Treatment?Kenneth Blum, Mark Gold, H Westley Clark, et al.
Molecular Neurobiology|March 10, 2015
Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner?Kenneth Blum, Marcelo Febo, Panayotis K Thanos, et al.
Journal of the Neurological Sciences|July 16, 2022
Psychedelic drugs for psychiatric disordersSabrina Correa da Costa, Tyler Oesterle, Teresa A Rummans, et al.
Brain Sciences|December 23, 2023
Exercise Modifies the Brain Metabolic Response to Chronic Cocaine Exposure Inhibiting the Stria TerminalisColin Hanna, Rutao Yao, Munawwar Sajjad, et al.
Pageof 5